Where Psychedelics Stand Now

The psychedelic-medicine policy landscape has changed more in the last 120 days than it did in the previous five years — and most of that movement is happening on tracks that are easy to confuse. Federal regulatory acceleration is one track. State-funded research is another. Compassionate-use and the gray-market clinic economy is a third. They are not the same, and they should not be discussed as if they are.

This spotlight is a clean-up: what is actually approved, what is in advanced trials, what the states are doing, and what to tell a family member or client who reads a headline and asks if they can get a psilocybin or ibogaine treatment now. (Short answer: not yet, with three legal exceptions we will name below.)

Science: two Phase 3 hits, with an asterisk

Compass Pathways announced on February 17, 2026 that COMP006, its second Phase 3 trial of COMP360 (a synthetic, proprietary psilocybin formulation) for treatment-resistant depression, hit its primary endpoint. Patients receiving two 25 mg doses three weeks apart showed a statistically significant -3.8-point reduction on the MADRS depression scale at week 6 versus a 1 mg comparator (p<0.001), with effects durable through 26 weeks for responders.

That is two consecutive Phase 3 wins, which is what FDA approval normally requires. But the effect size is modest. Psychedelic Alpha and STAT both flagged that the 3.8-point delta is smaller than what early-phase psilocybin trials suggested, and similar in magnitude to existing oral antidepressants. Compass plans to file an FDA application in 2026.

The other late-stage compound to know is methylone (from Transcend Therapeutics), an MDMA-similar empathogen being studied for PTSD. Transcend received one of the FDA’s three new Commissioner’s National Priority Vouchers (CNPVs) under the April 18 executive order, alongside Compass (psilocybin/TRD) and the nonprofit Usona Institute (psilocybin/major depressive disorder). The vouchers compress review timelines from the usual 10–12 months to 1–2 months.

Biology: ibogaine is the wildcard, and the U.S. just opened a door

Ibogaine is the compound most often discussed for opioid use disorder specifically. Anecdotal and small-trial data from clinics in Mexico, New Zealand, and the Czech Republic have for years described dramatic single-session reductions in opioid craving and withdrawal. The mechanism is poorly understood. The cardiac safety profile is real and concerning — QT prolongation has been linked to deaths in unsupervised clinic settings.

In April 2026, the FDA cleared the first U.S. human trial of noribogaine — ibogaine’s active metabolite, which appears to retain the anti-craving effects with a different and possibly safer cardiac profile. This is the first FDA-sanctioned U.S. research on the molecule and is being closely watched by both DEA and addiction-medicine researchers.

Policy: states are moving faster than the FDA, in two different directions

The most active state-level developments:

• Texas appropriated $50M of its opioid settlement money toward ibogaine research. This is the largest single state investment in psychedelic OUD research in U.S. history.
• Kentucky passed SB Douglas, a Republican-sponsored framework bill authorizing ibogaine research for PTSD and SUD, with an emergency clause that overrode Gov. Beshear’s veto and made it law immediately.
• Ohio’s REID Foundation announced a partnership with former Kentucky Opioid Abatement Commission Chair Bryan Hubbard to pursue FDA-authorized ibogaine trials in Ohio.
• Arizona is not currently part of this conversation, despite both higher overdose burden than any of those three states and the unspent settlement question we covered in today’s featured.
• Oregon and Colorado continue to operate state-licensed, non-clinical psilocybin services for adult use — distinct from FDA-track medicine.

Where the field disagrees

Three real, current debates among addiction-medicine and psychedelic-medicine researchers:

1. Therapy or molecule? The Compass effect size has reignited the question of whether psilocybin works because of the psychedelic experience itself, or whether the trial design (intensive therapy adjacent to dosing) is doing much of the work. The answer materially affects how it should be reimbursed and delivered.
2. Ibogaine: safer with what? Noribogaine’s cardiac profile looks better in animal data. Whether that holds in humans, and whether it retains the dramatic opioid-craving suppression ibogaine shows in clinic settings, is what the FDA-cleared trial is designed to answer.
3. State-licensed psilocybin services (Oregon, Colorado). These are not medical treatments. The clinical community is split on whether they are an additional access lane for people who would otherwise self-treat with street-sourced compounds, or a parallel system that complicates a still-emerging medical-grade pipeline.

What this means today, in May 2026

For people seeking treatment now: no psychedelic is FDA-approved for any indication (Spravato/esketamine is a derivative of ketamine and is approved, but that’s a different category). The three lanes that exist are: (1) clinical-trial enrollment via ClinicalTrials.gov; (2) state-licensed adult-use psilocybin in OR/CO; (3) compassionate-use protocols for terminal-illness contexts.

For people seeking treatment now: no psychedelic is FDA-approved for any indication (Spravato/esketamine is a derivative of ketamine and is approved, but that’s a different category).

If you or someone you love is searching for “psilocybin treatment” or “ibogaine clinic,” what we recommend instead is starting with proven, accessible options and treating the psychedelic pipeline as something to watch — not as the next thing to try this week.

If you are in crisis right now, call or text 988.